Back to Browse Journals » Patient Preference and Adherence » Volume 6

Subcutaneous delivery of sumatriptan in the treatment of migraine and primary headache

Authors Moore JC, Miner JR

Published Date January 2012 Volume 2012:6 Pages 27—37


Received 8 October 2011, Accepted 2 November 2011, Published 4 January 2012

Video presented by Johanna C Moore

Views: 589

Johanna C Moore, James R Miner
Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis, MN, USA

Abstract: Subcutaneous sumatriptan is an effective treatment for pain from acute migraine headache, and can be used in patients with known migraine syndrome and in patients with primary headaches when secondary causes have been excluded. In limited comparative trials, subcutaneous sumatriptan performed in a manner comparable with oral eletriptan and intravenous metoclopramide, was superior to intravenous aspirin and intramuscular trimethobenzamide-diphenhydramine, and was inferior to intravenous prochlorperazine for pain relief. The most common side effects seen with subcutaneous sumatriptan are injection site reactions and triptan sensations. As with all triptans, there is a risk of rare cardiovascular events with subcutaneous sumatriptan and its use should be limited to those without known cerebrovascular disease and limited in those with known cardiovascular risk factors and unknown disease status. In studies of patient preference and tolerability, the subcutaneous formulation has a faster time of onset and high rate of efficacy when compared with the oral formulation, but the oral formulation appears to be better tolerated. It is important to consider the needs of the patient, their past medical history, and what aspects of migraine treatment are most important to the patient when considering treatment of acute migraine or primary headache. Subcutaneous sumatriptan is a good first-line agent for the treatment of pain from acute migraine headaches and primary headaches.

Keywords: sumatriptan, subcutaneous, migraine headache, primary headache

Download Article [PDF] View Full Text [HTML] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at:

Readers of this article also read:

Effect of a network system for providing proper inhalation technique by community pharmacists on clinical outcomes in COPD patients

Takemura M, Mitsui K, Ido M, Matsumoto M, Koyama M, Inoue D, Takamatsu K, Itotani R, Ishitoko M, Suzuki S, Aihara K, Sakuramoto M, Kagioka H, Fukui M

International Journal of Chronic Obstructive Pulmonary Disease 2013, 8:239-244

Published Date: 9 May 2013

Guideline-based survey of outpatient COPD management by pulmonary specialists in Germany

Glaab T, Vogelmeier C, Hellmann A, Buhl R

International Journal of Chronic Obstructive Pulmonary Disease 2012, 7:101-108

Published Date: 14 February 2012

Plerixafor for autologous CD34+ cell mobilization

Huda Salman, Hillard M Lazarus

Core Evidence 2011, 6:23-29

Published Date: 8 February 2011

Concordance, compliance, preference or adherence

Scott Fraser

Patient Preference and Adherence 2010, 4:95-96

Published Date: 30 December 2010

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009

Comparisons of different mean airway pressure settings during high-frequency oscillation in inflammatory response to oleic acid-induced lung injury in rabbits

Koichi Ono, Tomonobu Koizumi, Rikimaru Nakagawa, Sumiko Yoshikawa, Tetsutarou Otagiri

Journal of Inflammation Research 2009, 2:21-28

Published Date: 16 March 2009